ME02485B - Bispecifično jednolančano protutijelo psmaxcd3 s međuvrsnom specifičnošću - Google Patents

Bispecifično jednolančano protutijelo psmaxcd3 s međuvrsnom specifičnošću

Info

Publication number
ME02485B
ME02485B MEP-2016-156A MEP15616A ME02485B ME 02485 B ME02485 B ME 02485B ME P15616 A MEP15616 A ME P15616A ME 02485 B ME02485 B ME 02485B
Authority
ME
Montenegro
Prior art keywords
cdr
seq
chain antibody
bispecific single
antibody molecule
Prior art date
Application number
MEP-2016-156A
Other languages
English (en)
French (fr)
Inventor
Doris Rau
Evelyne Schaller
Susanne Hausmann
Petra Fluhr
Carola Steiger
Peter Kufer
Tobias Raum
Roman Kischel
Ralf LUTTERBÜSE
Patrick Hoffmann
Susanne Mangold
Matthias Klinger
Original Assignee
Amgen Res Munich Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42073956&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02485(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Res Munich Gmbh filed Critical Amgen Res Munich Gmbh
Publication of ME02485B publication Critical patent/ME02485B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (18)

1. Molekula bispecifičnog jednolančanog protutijela, naznačena time što sadrži prvu vežuću domenu koja se specifično veže na epitop u lancu CD3ε kod čovjeka i Callithrix jacchus, Saguinus oedipus ili Saimiri sciureus, gdje je navedeni epitop dio aminokiselinskogi slijeda iz skupine koju čine SEQ ID NO. 2, 4, 6 ili 8, i u najmanju ruku sadrži aminokiselinski slijed Gln-Asp-Gly-Asn-Glu, te drugu vežuću domenu koja se veže na membranski antigen specifičan za prostatu (PSMA).
2. Molekula bispecifičnog jednolančanog protutijela u skladu s patentnim zahtjevom 1, naznačena time što prva vežuća domena sadrži područje VL, koje sadrži CDR-L1, CDR-L2 i CDR-L3, koje se bira između: (a) CDR-L1, kao što je opisan u SEQ ID NO. 27, CDR-L2, kao što je opisan u SEQ ID NO. 28 i CDR-L3, kao što je opisan u SEQ ID NO. 29; (b) CDR-L1, kao što je opisan u SEQ ID NO. 117, CDR-L2, kao što je opisan u SEQ ID NO. 118 i CDR-L3, kao što je opisan u SEQ ID NO. 119; i (c) CDR-L1, kao što je opisan u SEQ ID NO. 153, CDR-L2, kao što je opisan u SEQ ID NO. 154 i CDR-L3, kao što je opisan u SEQ ID NO. 155.
3. Molekula bispecifičnog jednolančanog protutijela u skladu s patentnim zahtjevom 1 ili 2, naznačena time što prva vežuća domena sadrži područje VH, koje sadrži CDR-H1, CDR-H2 i CDR-H3, koje se bira između: (a) CDR-H1, kao što je opisan u SEQ ID NO. 12, CDR-H2, kao što je opisan u SEQ ID NO. 13 i CDR-H3, kao što je opisan u SEQ ID NO. 14; (b) CDR-H1, kao što je opisan u SEQ ID NO. 30, CDR-H2, kao što je opisan u SEQ ID NO. 31 i CDR-H3, kao što je opisan u SEQ ID NO. 32; (c) CDR-H1, kao što je opisan u SEQ ID NO. 48, CDR-H2, kao što je opisan u SEQ ID NO. 49 i CDR-H3, kao što je opisan u SEQ ID NO. 50; (d) CDR-H1, kao što je opisan u SEQ ID NO. 66, CDR-H2, kao što je opisan u SEQ ID NO. 67 i CDR-H3, kao što je opisan u SEQ ID NO. 68; (e) CDR-H1, kao što je opisan u SEQ ID NO. 84, CDR-H2, kao što je opisan u SEQ ID NO. 85 i CDR-H3, kao što je opisan u SEQ ID NO. 86; (f) CDR-H1, kao što je opisan u SEQ ID NO. 102, CDR-H2, kao što je opisan u SEQ ID NO. 103 i CDR-H3, kao što je opisan u SEQ ID NO. 104; (g) CDR-H1, kao što je opisan u SEQ ID NO. 120, CDR-H2 kao što je opisan u SEQ ID NO. 121 i CDR-H3kao što je opisan u SEQ ID NO. 122; (h) CDR-H1, kao što je opisan u SEQ ID NO. 138, CDR-H2, kao što je opisan u SEQ ID NO. 139 i CDR-H3, kao što je opisan u SEQ ID NO. 140; (i) CDR-H1, kao što je opisan u SEQ ID NO. 156, CDR-H2, kao što je opisan u SEQ ID NO. 157 i CDR-H3, kao što je opisan u SEQ ID NO. 158; i (j) CDR-H1, kao što je opisan u SEQ ID NO. 174, CDR-H2, kao što je opisan u SEQ ID NO. 175 i CDR-H3, kao što je opisan u SEQ ID NO. 176.
4. Molekula bispecifičnog jednolančanog protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što se druga vežuća domena može vezati na ljudski PSMA i/ili na neljudski primatski PSMA.
5. Molekula bispecifičnog jednolančanog protutijela u skladu s patentnim zahtjevom 4, naznačena time što molekula bispecifičnog jednolančanog protutijela uključuje skupinu sljedećih sljedova poput CDR H1, CDR H2, CDR H3, CDR L1, CDR L2 i CDR L3 u drugoj vežućoj domeni koju se bira između: a) CDR H1-3 sa SEQ ID NO: 394-396 i CDR L1-3 sa SEQ ID NO: 389-391; b) CDR H1-3 sa SEQ ID NO: 408-410 i CDR L1-3 sa SEQ ID NO: 403-405; c) CDR H1-3 sa SEQ ID NO: 422-424 i CDR L1-3 sa SEQ ID NO: 417-419; d) CDR H1-3 sa SEQ ID NO: 436-438 i CDR L1-3 sa SEQ ID NO: 431-433; e) CDR H1-3 sa SEQ ID NO: 445-447 i CDR L1-3 sa SEQ ID NO: 450-452; f) CDR H1-3 sa SEQ ID NO: 464-466 i CDR L1-3 sa SEQ ID NO: 459-461; g) CDR H1-3 sa SEQ ID NO: 478-480 i CDR L1-3 sa SEQ ID NO: 473-475; h) CDR H1-3 sa SEQ ID NO: 492-494 i CDR L1-3 sa SEQ ID NO: 487-489; i) CDR H1-3 sa SEQ ID NO: 506-508 i CDR L1-3 sa SEQ ID NO: 501-503; j) CDR H1-3 sa SEQ ID NO: 520-522 i CDR L1-3 sa SEQ ID NO: 515-517; k) CDR H1-3 sa SEQ ID NO: 534-536 i CDR L1-3 sa SEQ ID NO: 529-531; l) CDR H1-3 sa SEQ ID NO: 548-550 i CDR L1-3 sa SEQ ID NO: 543-545; m) CDR H1-3 sa SEQ ID NO: 562-564 i CDR L1-3 sa SEQ ID NO: 557-559; n) CDR H1-3 sa SEQ ID NO: 576-578 i CDR L1-3 sa SEQ ID NO: 571-573; o) CDR H1-3 sa SEQ ID NO: 590-592 i CDR L1-3 sa SEQ ID NO: 585-587; p) CDR H1-3 sa SEQ ID NO: 604-606 i CDR L1-3 sa SEQ ID NO: 599-601; q) CDR H1-3 sa SEQ ID NO: 618-620 i CDR L1-3 sa SEQ ID NO: 613-615; r) CDR H1-3 sa SEQ ID NO: 632-634 i CDR L1-3 sa SEQ ID NO: 627-629; s) CDR H1-3 sa SEQ ID NO: 646-648 i CDR L1-3 sa SEQ ID NO: 641-643; t) CDR H1-3 sa SEQ ID NO: 660-662 i CDR L1-3 sa SEQ ID NO: 655-657; u) CDR H1-3 sa SEQ ID NO: 674-676 i CDR L1-3 sa SEQ ID NO: 669-671; v) CDR H1-3 sa SEQ ID NO: 688-690 i CDR L1-3 sa SEQ ID NO: 683-685; w) CDR H1-3 sa SEQ ID NO: 702-704 i CDR L1-3 sa SEQ ID NO: 697-699; x) CDR H1-3 sa SEQ ID NO: 716-718 i CDR L1-3 sa SEQ ID NO: 711-713; y) CDR H1-3 sa SEQ ID NO: 729-731 i CDR L1-3 sa SEQ ID NO: 724-726; z) CDR H1-3 sa SEQ ID NO: 788-790 i CDR L1-3 sa SEQ ID NO: 793-795; aa) CDR H1-3 sa SEQ ID NO: 806-808 i CDR L1-3 sa SEQ ID NO: 811-813; ab) CDR H1-3 sa SEQ ID NO: 852-854 i CDR L1-3 sa SEQ ID NO: 857-859; ac) CDR H1-3 sa SEQ ID NO: 838-840 i CDR L1-3 sa SEQ ID NO: 843-845; ad) CDR H1-3 sa SEQ ID NO: 824-826 i CDR L1-3 sa SEQ ID NO: 829-831; ae) CDR H1-3 sa SEQ ID NO: 774-776 i CDR L1-3 sa SEQ ID NO: 779-781; af) CDR H1-3 sa SEQ ID NO: 688-690 i CDR L1-3 sa SEQ ID NO: 683-685; ag) CDR H1-3 sa SEQ ID NO: 870-872 i CDR L1-3 sa SEQ ID NO: 875-877; ah) CDR H1-3 sa SEQ ID NO: 888-890 i CDR L1-3 sa SEQ ID NO: 893-895; ai) CDR H1-3 sa SEQ ID NO: 924-926 i CDR L1-3 sa SEQ ID NO: 929-931; aj) CDR H1-3 sa SEQ ID NO: 1019-1021 i CDR L1-3 sa SEQ ID NO: 1025-1027; ak) CDR H1-3 sa SEQ ID NO: 1006-1008 i CDR L1-3 sa SEQ ID NO: 1011-1013; al) CDR H1-3 sa SEQ ID NO: 906-908 i CDR L1-3 sa SEQ ID NO: 911-913; am) CDR H1-3 sa SEQ ID NO: 992-994 i CDR L1-3 sa SEQ ID NO: 997-999; an) CDR H1-3 sa SEQ ID NO: 942-944 i CDR L1-3 sa SEQ ID NO: 947-949; ao) CDR H1-3 sa SEQ ID NO: 960-962 i CDR L1-3 sa SEQ ID NO: 965-967; i ap) CDR H1-3 sa SEQ ID NO: 978-980 i CDR L1-3 sa SEQ ID NO: 983-985.
6. Molekula bispecifičnog jednolančanog protutijela u skladu s patentnim zahtjevom 5, naznačena time što vežuće domene idu redoslijedom VH PSMA-VL PSMA-VH CD3-VL CD3 ili VL PSMA-VH PSMA-VH CD3-VL CD3.
7. Molekula bispecifičnog jednolančanog protutijela u skladu s patentnim zahtjevom 6, naznačena time što molekula bispecifičnog jednolančanog protutijela ima slijed koji se bira između: (a) aminokiselinskog slijeda kao što je opisan u bilo kojem od SEQ ID NO: 399, 413, 427, 441, 455, 469, 483, 497, 511, 525, 539, 553, 567, 581, 595, 609, 623, 637, 651, 665, 679, 693, 707, 721, 734, 799, 817, 863, 849, 835, 785, 899, 935, 1017, 1031, 917, 1003, 953, 971 ili 989; (b) aminokiselinskog slijeda kojeg kodira nukleinskokiselinski slijed kao što je opisan u bilo kojem od SEQ ID NO: 400, 414, 428, 442, 456, 470, 484,498, 512, 526, 540, 554, 568, 582, 596, 610, 624, 638, 652, 666, 680, 694, 708, 736 735, 800, 818, 864, 850, 836, 786, 882, 900, 936, 1018, 1032, 918, 1004, 954, 972, 990, 804, 822, 868, 886, 904, 940, 922, 958 ili 976; i (c) aminokiselinskog slijeda koji je najmanje 90% identičan, poželjnije najmanje 95% identičan, a najpoželjnije najmanje 96% identičan aminokiselinskom slijedu iz (a) ili (b).
8. Nukleinskokiselinski slijed, naznačen time što kodira molekulu bispecifičnog jednolančanog protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 7.
9. Vektor, naznačen time što sadrži nukleinskokiselinski slijed u skladu s patentnim zahtjevom 8.
10. Stanica domaćin, naznačena time što je transformirana ili transficirana vektorom u skladu s bilo kojim od patentnih zahtjeva 6 do 9.
11. Postupak proizvodnje molekule bispecifičnog jednolančanog protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što se navedeni postupak sastoji u uzgoju stanice domaćina u skladu s patentnim zahtjevom 10 u uvjetima koji omogućuju eksprimiranje molekule bispecifičnog jednolančanog protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 7 i prikupljanju proizvedenog polipeptida iz kulture.
12. Farmaceutski pripravak, naznače time što sadrži molekulu bispecifičnog jednolančanog protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 7, ili proizvedenu postupkom u skladu s patentnim zahtjevom 11.
13. Molekula bispecifičnog jednolančanog protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 7, ili proizvedena postupkom u skladu s patentnim zahtjevom 11, naznačena time što je namijenjena upotrebi u sprječavanju, liječenju ili ublažavanju raka.
14. Molekula bispecifičnog jednolančanog protutijela u skladu s patentnim zahtjevom 13, naznačena time što je navedeni rak čvrsti tumor, po mogućnosti karcinom ili rak prostate.
15. Komplet, naznačen time što sadrži molekulu bispecifičnog jednolančanog protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 7, molekula nukleinske kiseline u skladu s patentnim zahtjevom 8, vektor u skladu s patentnim zahtjevom 9, ili stanicu domaćina u skladu s patentnim zahtjevom 10.
16. Molekula bispecifičnog jednolančanog protutijela u skladu s patentnim zahtjevom 1, naznačena time što se navedena prva vežuća domena veže na N-terminalni CD3ε polipeptidni fragment in vitro i na nativnu CD3ε podjedinicu CD3 kompleksa na T-stanicama in vivo s istim afinitetom vezanja.
17. Molekula bispecifičnog jednolančanog protutijela u skladu s patentnim zahtjevom 1, naznačena time što je navedeni epitop dio aminokiselinskog slijeda koji se sastoji od 26, 25, 24, 23, 22, 21 ,20, 19, 18, 17, 16, 15, 14, 13, 12, 11 , 10, 9, 8, 7, 6 ili 5 aminokiselina.
18. Molekula bispecifičnog jednolančanog protutijela u skladu s patentnim zahtjevom 1, naznačena time što je homogenost molekule bispecifičnog jednolančanog protutijela najmanje 90%, 95% ili 98%.
MEP-2016-156A 2008-10-01 2009-10-01 Bispecifično jednolančano protutijelo psmaxcd3 s međuvrsnom specifičnošću ME02485B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10185708P 2008-10-01 2008-10-01
EP09783664.7A EP2356153B1 (en) 2008-10-01 2009-10-01 Cross-species-specific psmaxcd3 bispecific single chain antibody
PCT/EP2009/062793 WO2010037836A2 (en) 2008-10-01 2009-10-01 Cross-species-specific psmaxcd3 bispecific single chain antibody

Publications (1)

Publication Number Publication Date
ME02485B true ME02485B (me) 2017-02-20

Family

ID=42073956

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2016-156A ME02485B (me) 2008-10-01 2009-10-01 Bispecifično jednolančano protutijelo psmaxcd3 s međuvrsnom specifičnošću

Country Status (26)

Country Link
US (6) US20110293619A1 (me)
EP (3) EP2356153B1 (me)
JP (4) JP6126782B2 (me)
KR (1) KR101820535B1 (me)
CN (1) CN102171248B (me)
AU (1) AU2009299792B2 (me)
BR (1) BRPI0919841A2 (me)
CA (1) CA2738565C (me)
CY (1) CY1118303T1 (me)
DK (1) DK2356153T3 (me)
ES (1) ES2588155T3 (me)
HR (1) HRP20160684T1 (me)
HU (1) HUE030090T2 (me)
IL (1) IL212099A (me)
ME (1) ME02485B (me)
MX (1) MX2011003502A (me)
NZ (1) NZ591134A (me)
PL (1) PL2356153T3 (me)
PT (1) PT2356153T (me)
RS (1) RS54900B1 (me)
RU (1) RU2559531C2 (me)
SG (1) SG194398A1 (me)
SI (1) SI2356153T1 (me)
SM (1) SMT201600256B (me)
WO (1) WO2010037836A2 (me)
ZA (1) ZA201101067B (me)

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101589759B1 (ko) * 2007-04-03 2016-01-29 암젠 리서치 (뮌헨) 게엠베하 종간 특이적 ｃｄ３―입실론 결합 도메인
AU2009299794B2 (en) * 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
BRPI0919841A2 (pt) * 2008-10-01 2014-11-18 Micromet Ag Anticorpo de cadeia unica biespecifico de psmaxcd3, especifico de especies cruzadas
AU2010249719A1 (en) 2009-05-19 2012-05-31 Aic Blab Company Composite current collector and methods therefor
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
CA2806252C (en) 2010-07-29 2019-05-14 Xencor, Inc. Antibodies with modified isoelectric points
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
LT2647707T (lt) 2010-11-30 2018-11-12 Chugai Seiyaku Kabushiki Kaisha Citotoksiškumą indukuojantis terapinis agentas
SG194510A1 (en) * 2011-04-22 2013-12-30 Emergent Product Dev Seattle Prostate-specific membrane antigen binding proteins and related compositionsand methods
EP2710042A2 (en) * 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
WO2013026839A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
US20150037334A1 (en) 2012-03-01 2015-02-05 Amgen Research (Munich) Gmbh Long life polypeptide binding molecules
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
EP2900696A1 (en) * 2012-09-25 2015-08-05 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
EP2916866B1 (de) * 2012-11-06 2018-04-04 Bayer Pharma Aktiengesellschaft Formulierung für bispecific t-cell-engangers (bites)
CN103087171B (zh) * 2012-12-24 2015-01-14 中国人民解放军第四军医大学 一种用于前列腺癌早期诊断和治疗的抗psma/fitc双特异性抗体及其制备方法
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
HRP20191865T1 (hr) 2013-01-14 2020-01-10 Xencor, Inc. Novi heterodimerni proteini
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
EP2762497A1 (en) 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
PL2953972T3 (pl) 2013-02-05 2021-03-08 Engmab Sàrl Metoda wyboru przeciwciał przeciwko bcma
JO3529B1 (ar) * 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
CA3093606A1 (en) 2013-03-15 2014-09-18 Xencor, Inc. Heterodimeric proteins for induction of t cells
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
AU2014236769B2 (en) * 2013-03-15 2018-09-27 Amgen Inc. Heterodimeric bispecific antibodies
WO2014143886A2 (en) * 2013-03-15 2014-09-18 Edimer Pharmaceuticals, Inc. Anti-ectodysplasin antibodies
EP2970446A1 (en) 2013-03-15 2016-01-20 Amgen Research (Munich) GmbH Antibody constructs for influenza m2 and cd3
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
CA2918795A1 (en) 2013-07-25 2015-01-29 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
EP3954713A3 (en) 2014-03-28 2022-03-30 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
US9884921B2 (en) 2014-07-01 2018-02-06 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
US9212225B1 (en) * 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
WO2016014974A2 (en) * 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
EP3223907A2 (en) 2014-11-26 2017-10-04 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
CN116333153A (zh) 2014-11-26 2023-06-27 森科股份有限公司 结合cd3和肿瘤抗原的异二聚体抗体
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
EP3247725B1 (en) 2015-01-23 2020-07-01 Sanofi Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
CA2976360A1 (en) * 2015-02-11 2016-08-18 Aptevo Research And Development Llc Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
CN111234027A (zh) 2015-05-21 2020-06-05 哈普恩治疗公司 三特异性结合蛋白质及使用方法
KR102537102B1 (ko) 2015-05-29 2023-05-25 엠피베나 테라퓨틱스, 인크. 이중특이적 cd33 및 cd3 결합 단백질을 사용하는 방법
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
JOP20160154B1 (ar) * 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
PT3331910T (pt) 2015-08-03 2020-03-24 Engmab Sarl Anticorpos monoclonais contra o antigénio de maturação de células b (bcma) humano
PT3337824T (pt) 2015-08-17 2020-09-10 Janssen Pharmaceutica Nv Anticorpos anti-bcma, moléculas de ligação a antigénio biespecíficas que ligam bcma e cd3, e suas utilizações
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
CN105198992B (zh) * 2015-10-16 2018-07-13 中国人民解放军海军总医院 一种人源抗创伤弧菌溶血素蛋白(vvh)抗体的制备方法与应用
EP3371220A2 (en) 2015-11-02 2018-09-12 Janssen Pharmaceutica NV Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof
KR20180085800A (ko) * 2015-12-07 2018-07-27 젠코어 인코포레이티드 Cd3 및 psma에 결합하는 이종이합체성 항체
LT3411404T (lt) * 2016-02-03 2022-12-27 Amgen Research (Munich) Gmbh Psma ir cd3 bispecifiniai, t ląsteles aktyvuojantys antikūno konstruktai
JP7034489B2 (ja) 2016-03-15 2022-03-14 アイタブメッド （エイチケイ） リミテッド 多重特異性Ｆａｂ融合タンパクおよびその使用
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
BR112018073739A2 (pt) 2016-05-20 2019-02-26 Harpoon Therapeutics, Inc. proteína de ligação de albumina sérica de domínio único
IL263542B2 (en) 2016-06-14 2024-10-01 Xencor Inc Bispecific antibodies inhibit immunological checkpoint
EP3471773A4 (en) 2016-06-21 2020-07-08 Teneobio, Inc. ANTIBODIES BINDING CD3
KR20190020341A (ko) 2016-06-28 2019-02-28 젠코어 인코포레이티드 소마토스타틴 수용체 2에 결합하는 이종이량체 항체
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
UA126384C2 (uk) * 2016-09-14 2022-09-28 Тенеобіо, Інк. Антитіло, яке зв'язує cd3
EP3515491A4 (en) 2016-09-21 2020-09-16 Aptevo Research and Development LLC CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND PROCESSES
CN110214148A (zh) 2016-10-14 2019-09-06 Xencor股份有限公司 含有IL-15/IL-15Rα Fc融合蛋白和PD-1抗体片段的双特异性异源二聚体融合蛋白
US11124577B2 (en) 2016-11-02 2021-09-21 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
JP6812551B2 (ja) 2016-11-23 2021-01-13 ハープーン セラピューティクス，インク． 前立腺特異的膜抗原結合タンパク質
JP7215997B2 (ja) * 2016-11-23 2023-01-31 ハープーン セラピューティクス，インク． 前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法
IL267485B2 (en) 2016-12-21 2024-01-01 Teneobio Inc Anti-bcma heavy chain-only antibodies and uses thereof
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
TWI710637B (zh) * 2017-03-29 2020-11-21 臺北醫學大學 具抗原專一性的t細胞及其用途
CA3063359A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Mesothelin binding proteins
CN110945026B (zh) 2017-06-20 2024-03-19 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
KR20250007003A (ko) 2017-06-20 2025-01-13 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
US10882907B2 (en) 2017-06-21 2021-01-05 Gilead Sciences, Inc. Multispecific antibodies that target HIV GP120 and CD3
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
CA3071376A1 (en) 2017-08-03 2019-02-07 Amgen Inc. Interleukin-21 muteins and methods of treatment
EP3679040B1 (en) 2017-09-08 2022-08-03 Amgen Inc. Inhibitors of kras g12c and methods of using the same
EA202090800A1 (ru) 2017-09-21 2020-08-11 Уси Байолоджикс Аэлэнд Лимитед Новые анти-cd3-эпсилон антитела
US12486325B2 (en) 2017-09-21 2025-12-02 WuXi Biologics Ireland Limited Anti-CD3epsilon antibodies
UA129446C2 (uk) 2017-10-13 2025-04-30 Гарпун Терап'Ютікс, Інк. Триспецифічні білки і способи їх застосування
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
IL321773A (en) 2017-10-14 2025-08-01 Cytomx Therapeutics Inc Activatable antibodies and methods for preparing them
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US10426424B2 (en) 2017-11-21 2019-10-01 General Electric Company System and method for generating and performing imaging protocol simulations
MX2020006322A (es) 2017-12-19 2020-09-18 Xencor Inc Proteinas de fusion il-2 fc modificadas.
MX2020006494A (es) 2017-12-22 2020-11-24 Teneobio Inc Anticuerpos de cadena pesada que se unen a cd22.
TW201940518A (zh) 2017-12-29 2019-10-16 美商安進公司 針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
AU2019207895A1 (en) 2018-01-12 2020-06-18 Amgen Inc. Anti-PD-1 antibodies and methods of treatment
CN112469477A (zh) 2018-04-04 2021-03-09 Xencor股份有限公司 与成纤维细胞活化蛋白结合的异源二聚体抗体
IL323061A (en) 2018-04-11 2025-10-01 Inhibrx Biosciences Inc Multispecific polypeptide constructs with forced CD3 binding and related methods and uses
AU2019256539A1 (en) 2018-04-18 2020-11-26 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
EP3781598A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
WO2019222283A1 (en) 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Binding moiety for conditional activation of immunoglobulin molecules
AU2019270624B2 (en) 2018-05-16 2024-05-02 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics
JOP20200303A1 (ar) * 2018-05-24 2020-11-23 Janssen Biotech Inc عوامل ربط psma واستخداماتها
JOP20190116A1 (ar) 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
TWI848951B (zh) 2018-06-01 2024-07-21 瑞士商諾華公司 針對ｂｃｍａ之結合分子及其用途
US11555071B2 (en) 2018-06-03 2023-01-17 Lamkap Bio Beta Ltd. Bispecific antibodies against CEACAM5 and CD47
CN112789294A (zh) 2018-07-24 2021-05-11 印希比股份有限公司 含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法
FI3830132T3 (fi) 2018-07-31 2023-01-13 Humanisoituja vasta-aineita psma:ta vastaan
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
EP3856771A4 (en) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
CA3115089A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
AU2020232605A1 (en) 2019-03-01 2021-10-21 Xencor, Inc. Heterodimeric antibodies that bind ENPP3 and CD3
CN113710707B (zh) 2019-04-05 2024-05-31 特尼奥生物股份有限公司 结合于psma的重链抗体
MA55718A (fr) * 2019-04-19 2022-02-23 Janssen Biotech Inc Méthodes de traitement du cancer du rein avec un anticorps anti-psma/cd3
KR20220002899A (ko) 2019-04-19 2022-01-07 얀센 바이오테크 인코포레이티드 항-psma/cd3 항체로 전립선암을 치료하는 방법
BR112021023048A2 (pt) 2019-05-21 2022-04-19 Novartis Ag Moléculas de ligação a cd19 e usos das mesmas
CN119564852A (zh) 2019-06-14 2025-03-07 特尼奥生物股份有限公司 与cd22和cd3结合的多特异性重链抗体
TWI889320B (zh) 2019-07-05 2025-07-01 日商小野藥品工業股份有限公司 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療
CN119614577A (zh) * 2019-07-26 2025-03-14 艾夏卡法国有限公司 用于细胞靶向和标记的抗cd3核酸适配体
US12441807B2 (en) 2019-09-18 2025-10-14 Lamkap Bio Alpha AG Bispecific antibodies against CEACAM5 and CD3
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
EP3842461A1 (en) * 2019-12-23 2021-06-30 Albert-Ludwigs-Universität Freiburg Chimeric antigen receptors that bind to prostate specific membrane antigen
AU2021207470A1 (en) 2020-01-13 2022-07-07 Aptevo Research And Development Llc Formulations for protein therapeutics
BR112022013730A2 (pt) 2020-01-13 2022-10-11 Aptevo Res & Development Llc Métodos e composições para prevenir a adsorção de proteínas terapêuticas aos componentes do sistema de distribuição de drogas
IL295448A (en) 2020-02-21 2022-10-01 Harpoon Therapeutics Inc flt3 binding proteins and methods of use
CN115715220A (zh) 2020-04-29 2023-02-24 特尼奥生物股份有限公司 具有经修饰重链恒定区的多特异性重链抗体
IL298046A (en) 2020-05-11 2023-01-01 Janssen Biotech Inc Methods for treating multiple myeloma
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
KR102607909B1 (ko) 2020-08-19 2023-12-01 젠코어 인코포레이티드 항-cd28 조성물
CA3194771A1 (en) 2020-09-16 2022-03-24 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
WO2022060878A1 (en) 2020-09-16 2022-03-24 Amgen Inc. Methods for treating prostate cancer
US20240043565A1 (en) * 2020-10-15 2024-02-08 Janux Therapeutics, Inc. Antibodies targeting psma and cd3 and uses thereof
CR20230235A (es) * 2020-11-06 2023-10-05 Amgen Res Munich Gmbh Construcciones polipeptídicas que se unen selectivamente a cldn6 y cd3
CR20230229A (es) 2020-11-06 2023-09-05 Amgen Res Munich Gmbh Moléculas de unión a antígeno biespecíficas con múltiples dianas de selectividad aumentada
MX2023006817A (es) 2020-12-09 2023-08-14 Janux Therapeutics Inc Composiciones y metodos relacionados con anticuerpos activados por tumores dirigidos a psma y antigenos de celulas efectoras.
US20220267438A1 (en) 2021-02-16 2022-08-25 Janssen Pharmaceutica Nv Trispecific antibody targeting bcma, gprc5d, and cd3
JP2024511319A (ja) 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
MX2023011267A (es) 2021-03-24 2023-12-14 Janssen Biotech Inc Anticuerpo triespecífico dirigido a cd79b, cd20, y cd3.
EP4330281A1 (en) 2021-04-29 2024-03-06 Amgen Inc. Methods for reducing low molecular weight species of recombinantly-produced proteins
US20240384006A1 (en) 2021-05-06 2024-11-21 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
WO2022246244A1 (en) 2021-05-21 2022-11-24 Aptevo Research And Development Llc Dosing regimens for protein therapeutics
CN115536740A (zh) * 2021-06-30 2022-12-30 苏州方德门达新药开发有限公司 介导细胞内有效滞留cd3的空间构象表位及其应用
JP7707835B2 (ja) * 2021-10-06 2025-07-15 株式会社三洋物産 遊技機
JP7707836B2 (ja) * 2021-10-06 2025-07-15 株式会社三洋物産 遊技機
JP7707822B2 (ja) * 2021-10-06 2025-07-15 株式会社三洋物産 遊技機
JP7707834B2 (ja) * 2021-10-06 2025-07-15 株式会社三洋物産 遊技機
JP7707820B2 (ja) * 2021-10-06 2025-07-15 株式会社三洋物産 遊技機
JP7707823B2 (ja) * 2021-10-06 2025-07-15 株式会社三洋物産 遊技機
JP7707821B2 (ja) * 2021-10-06 2025-07-15 株式会社三洋物産 遊技機
JP7707827B2 (ja) * 2021-10-06 2025-07-15 株式会社三洋物産 遊技機
JP7707829B2 (ja) * 2021-10-06 2025-07-15 株式会社三洋物産 遊技機
JP7707832B2 (ja) * 2021-10-06 2025-07-15 株式会社三洋物産 遊技機
JP7707831B2 (ja) * 2021-10-06 2025-07-15 株式会社三洋物産 遊技機
JP7707824B2 (ja) * 2021-10-06 2025-07-15 株式会社三洋物産 遊技機
JP7707833B2 (ja) * 2021-10-06 2025-07-15 株式会社三洋物産 遊技機
JP7707825B2 (ja) * 2021-10-06 2025-07-15 株式会社三洋物産 遊技機
JP7707830B2 (ja) * 2021-10-06 2025-07-15 株式会社三洋物産 遊技機
JP7707828B2 (ja) * 2021-10-06 2025-07-15 株式会社三洋物産 遊技機
AU2022380722A1 (en) 2021-11-03 2024-06-20 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
WO2023183231A1 (en) 2022-03-21 2023-09-28 Amgen Inc. Combination therapy methods with t-cell engaging molecules for treatment of prostate cancer
IL316597A (en) 2022-05-12 2024-12-01 Amgen Res Munich Gmbh Multi-chain, multi-purpose, bispecific antigen-binding compounds with enhanced sensitivity
WO2025134049A1 (en) 2023-12-21 2025-06-26 Janssen Biotech, Inc Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis
WO2025134050A1 (en) 2023-12-21 2025-06-26 Janssen Biotech, Inc Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9304200D0 (en) 1993-03-02 1993-04-21 Sandoz Ltd Improvements in or relating to organic compounds
JP3626187B2 (ja) 1993-06-07 2005-03-02 バイカル インコーポレイテッド 遺伝子治療に適するプラスミド
AU723325B2 (en) 1995-06-23 2000-08-24 President And Fellows Of Harvard College Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
KR100508289B1 (ko) 1998-04-21 2005-08-17 마이크로메트 에이지 Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
US20020142000A1 (en) * 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
SE524615C2 (sv) 1999-06-30 2004-09-07 Volvo Personvagnar Ab Arrangemang för minskning av galvanisk korrosion mellan metallkomponenter
ATE342282T1 (de) * 1999-07-29 2006-11-15 Medarex Inc Humane monoklonale antikörper gegen prostata spezifisches membranantigen
JP4386776B2 (ja) * 2000-05-18 2009-12-16 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
RU2179862C1 (ru) * 2000-12-26 2002-02-27 Общество с ограниченной ответственностью Научно-производственный центр "МедБиоСпектр" Лекарственное средство для предотвращения отторжения трансплантата, моноклональное антитело к cd3-антигену т-лимфоцитов человека, гибридома и способ лечения больных, имеющих реакцию острого отторжения трансплантата после пересадки почки
CN1652821A (zh) * 2002-01-28 2005-08-10 米德列斯公司 抗前列腺特异性膜抗原(psma)的人单克隆抗体
AU2004210088A1 (en) * 2003-02-06 2004-08-19 Micromet Ag Trimeric polypeptide construct to induce an enduring T cell response
CA2522586C (en) * 2003-05-31 2017-02-21 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
CA2523716C (en) 2003-05-31 2014-11-25 Micromet Ag Human anti-human cd3 binding molecules
KR101229731B1 (ko) 2003-10-16 2013-03-07 암젠 리서치 (뮌헨) 게엠베하 다중특이적 탈면역화된 ｃｄ3-바인더
US7235641B2 (en) * 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
AU2005212830B2 (en) * 2004-02-16 2011-06-02 Amgen Research (Munich) Gmbh Less immunogenic binding molecules
ES2526343T3 (es) 2004-06-03 2015-01-09 Novimmune Sa Anticuerpos anti-CD3 y métodos de uso de los mismos
EA010374B1 (ru) * 2004-07-16 2008-08-29 Микромет Аг Полипептиды с повышенной экспрессией
JP2006040495A (ja) 2004-07-30 2006-02-09 Renesas Technology Corp 半導体集積回路装置
NO20064183L (no) 2005-02-16 2006-11-08 Micromet Ag Mindre immunogene bindingsmolekyler
JP2008529556A (ja) * 2005-02-18 2008-08-07 メダレックス， インク． 前立腺特異的膜抗原（ｐｓｍａ）に対するヒトモノクローナル抗体
EP1726650A1 (en) * 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
US20100209437A1 (en) 2005-09-12 2010-08-19 Greg Elson Anti-CD3 Antibody Fromulations
ES2856451T3 (es) * 2005-10-11 2021-09-27 Amgen Res Munich Gmbh Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas
KR101589759B1 (ko) * 2007-04-03 2016-01-29 암젠 리서치 (뮌헨) 게엠베하 종간 특이적 ｃｄ３―입실론 결합 도메인
AU2008234019B2 (en) 2007-04-03 2014-05-29 Amgen Research (Munich) Gmbh Cross-species-specific bispecific binders
PT2155783E (pt) * 2007-04-03 2013-11-07 Amgen Res Munich Gmbh Domínio de ligação específico inter-espécies
JP4970211B2 (ja) * 2007-10-18 2012-07-04 ヘキサゴン・メトロジー株式会社 ３次元形状測定器
EP2352763B2 (en) * 2008-10-01 2022-09-21 Amgen Research (Munich) GmbH Bispecific single chain antibodies with specificity for high molecular weight target antigens
BRPI0919841A2 (pt) * 2008-10-01 2014-11-18 Micromet Ag Anticorpo de cadeia unica biespecifico de psmaxcd3, especifico de especies cruzadas
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
LT3411404T (lt) * 2016-02-03 2022-12-27 Amgen Research (Munich) Gmbh Psma ir cd3 bispecifiniai, t ląsteles aktyvuojantys antikūno konstruktai

Also Published As

Publication number Publication date
US20110293619A1 (en) 2011-12-01
WO2010037836A9 (en) 2011-05-05
CA2738565C (en) 2023-10-10
DK2356153T3 (en) 2016-07-04
US20210277143A1 (en) 2021-09-09
US11472886B2 (en) 2022-10-18
AU2009299792B2 (en) 2015-07-16
SG194398A1 (en) 2013-11-29
HRP20160684T1 (hr) 2016-07-15
PT2356153T (pt) 2016-07-15
JP2016000736A (ja) 2016-01-07
NZ591134A (en) 2012-08-31
JP6643822B2 (ja) 2020-02-12
US12281172B2 (en) 2025-04-22
KR20110066195A (ko) 2011-06-16
SI2356153T1 (sl) 2016-07-29
RU2559531C2 (ru) 2015-08-10
US20230037742A1 (en) 2023-02-09
AU2009299792A1 (en) 2010-04-08
EP2356153A2 (en) 2011-08-17
WO2010037836A2 (en) 2010-04-08
HK1158669A1 (zh) 2012-07-20
MX2011003502A (es) 2011-09-01
ES2588155T3 (es) 2016-10-31
US20250163179A1 (en) 2025-05-22
IL212099A (en) 2016-02-29
IL212099A0 (en) 2011-06-30
CN102171248B (zh) 2015-07-15
KR101820535B1 (ko) 2018-01-19
EP2356153B1 (en) 2016-05-04
SMT201600256B (it) 2016-08-31
WO2010037836A3 (en) 2010-07-22
CN102171248A (zh) 2011-08-31
JP2012504403A (ja) 2012-02-23
JP2021164459A (ja) 2021-10-14
JP2018198595A (ja) 2018-12-20
HUE030090T2 (en) 2017-04-28
BRPI0919841A2 (pt) 2014-11-18
RU2011108687A (ru) 2012-11-10
RS54900B1 (sr) 2016-10-31
JP7273106B2 (ja) 2023-05-12
CA2738565A1 (en) 2010-04-08
US20210269550A1 (en) 2021-09-02
PL2356153T3 (pl) 2016-11-30
EP4180458A1 (en) 2023-05-17
JP6126782B2 (ja) 2017-05-10
CY1118303T1 (el) 2017-06-28
EP3106468A1 (en) 2016-12-21
US20190169310A1 (en) 2019-06-06
ZA201101067B (en) 2013-03-27

Similar Documents

Publication Publication Date Title
ME02485B (me) Bispecifično jednolančano protutijelo psmaxcd3 s međuvrsnom specifičnošću
JP2012504403A5 (me)
HRP20120759T1 (hr) Bispecifična veziva specifična između vrsta
HRP20130883T4 (hr) Međuvrsno specifična cd3-epsilon-vežuća domena
FI2155783T4 (fi) Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni
HRP20160857T1 (hr) Bispecifična jednolančana protutijela, specifična za visokomolekulske ciljne antigene
SI9720020B (en) Human antibodies that bind human TNF alpha
JP2005518336A5 (me)
CA2420231A1 (en) Antibodies to human il-1.beta.
JP2019006820A (ja) 多重特異性多価抗体の生成方法
JP2010524435A5 (me)
RU2011116927A (ru) Антитела против интерлейкина 17 (ил-17) человека и их применение
JP2007526880A5 (me)
CA2401342A1 (en) Human antibodies against eotaxin and their use
HRP20231410T1 (hr) Konstrukti bispecifičnih antitijela koji vežu mezotelin i cd3
JP2005522514A5 (me)
SI2753646T1 (en) Anti-CD40 antibodies, uses and methods
HRP20191983T1 (hr) Konstrukti protutijela za cdh19 i cd3
KR20130010123A (ko) ＴＮＦ-α 결합 단백질
NZ591087A (en) Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
RU2009124591A (ru) Соединения
HRP20110187T1 (hr) Multispecifične deimunizirane tvari koje vežu cd3
CN108164600B (zh) 一种抗gpc3抗体及其制备方法和用途
MY137078A (en) Recombinant antibodies associated to gangliosides. their use indiagnosis and treatment of tumors.
JP2021509012A5 (me)